Plain-English translation of NCT06593431 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The EXPAND trial is testing a new approach for people with pancreatic cancer that has spread to a few distant sites in the body. Researchers want to see if treating all cancer spots — using focused radiation, surgery, or other targeted local treatments — plus chemotherapy works better than chemotherapy alone. The goal is to help people live longer and feel better.
Most pancreatic cancer patients receive only chemotherapy when their cancer has spread. But doctors think that combining this medication with focused treatments aimed directly at each cancer spot might stop the disease from growing faster and help people survive longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one group receives chemotherapy plus focused treatments (radiation, surgery, or other targeted therapies) to all cancer spots, and the other group receives chemotherapy alone. You will have regular visits for scans, blood work, and check-ins to see how you are doing. The trial will track how long you survive, whether new cancers appear, and how the treatment affects your quality of life over time.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States